Bullish
Telix study showed low kidney, salivary gland uptake in prostate cancer
Telix Pharmaceuticals presented Phase 2 OPTIMAL-PSMA data for TLX597-Tx, a prostate cancer therapeutic, showing low uptake in salivary glands and kidn...